Clarithromycin/clofazimine/rifabutin - RedHill Biopharma

Drug Profile

Clarithromycin/clofazimine/rifabutin - RedHill Biopharma

Alternative Names: Clarithromycin/rifabutin/clofazimine; Clofazimine/clarithromycin/rifabutin; Clofazimine/rifabutin/clarithromycin; Myoconda®; RHB 204; RHB-104; Rifabutin/clarithromycin/clofazimine; Rifabutin/clofazimine/clarithromycin

Latest Information Update: 28 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Centre for Digestive Diseases
  • Developer RedHill Biopharma
  • Class Anti-inflammatories; Antibacterials; Macrolides; Phenazines; Rifamycins
  • Mechanism of Action Adenosine triphosphatase inhibitors; P-glycoprotein inhibitors; Phospholipase A2 inhibitors; Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Crohn's disease
  • New Molecular Entity No

Highest Development Phases

  • Phase III Crohn's disease
  • Phase II Multiple sclerosis
  • Phase I/II Mycobacterial infections
  • Preclinical Rheumatoid arthritis; Systemic lupus erythematosus
  • No development reported Psoriasis; Type 1 diabetes mellitus

Most Recent Events

  • 28 Oct 2018 No recent reports of development identified for preclinical development in Psoriasis in Israel
  • 22 Oct 2018 Additional efficacy data from the phase III MAP US trial in Crohn's disease released by RedHill Biopharma
  • 13 Aug 2018 RedHill Biopharma receives Notice of Allowance for RHB 104 and RHB 204 in Crohn's disease and Mycobacterial infections, respectively in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top